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Abstract
Skp1–cullin–F-box protein (SCF) is a multicomponent
E3 ubiquitin (Ub) ligase that ubiquitinates a number of
important biologic molecules such as p27, B-catenin,
and IKB for proteasomal degradation, thus regulating
cell proliferation and survival. One SCF component,
SAG/ROC2/Rbx2/Hrt2, a RING finger protein, was first
identified as a redox-inducible protein, which, when
overexpressed, inhibited apoptosis both in vitro and
in vivo. We report here that sensitive to apoptosis gene
(SAG), as well as its family member ROC1/Rbx1, bound
to the proinactive form of caspase-3 (pro–caspase-3).
Binding was likely mediated through F-box protein,
B-transducin repeat-containing protein (B-TrCP), which
binds to the first 38 amino acids of pro–caspase-3. Im-
portantly, B-TrCP1 expression significantly shortened
the protein half-life of pro–caspase-3, whereas ex-
pression of a dominant-negative B-TrCP1 mutant with
the F-box domain deleted extended it. An in vitro
ubiquitination assay showed that SAG/ROC–SCFB-TrCP
promoted ubiquitination of pro–caspase-3. Further-
more, endogenous levels of pro–caspase-3 were de-
creased by overexpression of SAG/ROC–SCFB-TrCP E3
Ub ligases, but increased on siRNA silencing of SAG,
regulator of cullin-1 (ROC1), or B-TrCPs, leading to in-
creased apoptosis by etoposide and TNF-related
apoptosis-inducing ligand through increased activation
of caspase-3. Thus, pro–caspase-3 appears to be a sub-
strate of SAG/ROC–SCFB-TrCP E3 Ub ligase, which pro-
tects cells from apoptosis through increased apoptosis
threshold by reducing the basal level of pro–caspase-3.
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Introduction
Apoptosis is a genetically programmed process of cell death
required for maintaining homeostasis under physiological
conditions and for responding to various internal and exter-
nal stimuli [1]. Cells committed to apoptosis are characterized
by membrane blebbing, cytoplasmic shrinkage, nuclear chro-
matin condensation, and DNA fragmentation [2]. Among many
molecular players that regulate apoptosis, caspases, a family
of cysteine proteases, play a critical and essential role. Cas-
pases exist in cells in an inactive prozymogen form [proinactive
form of caspase-3 (pro–caspases)]. Two major pathways in
apoptosis-associated caspase activation have been defined in
mammalian cells: the extrinsic death receptor pathway, which is
triggered by members of the death receptor superfamily, and
the intrinsic mitochondrial pathway, which is activated in re-
sponse to extracellular cues and internal insults, such as DNA
damage [3]. Both pathways converge at caspase-3, whose
activation, through proteolytic cleavage by other initiator cas-
pases, leads to the cleavage of many cellular protein substrates
and to committed apoptotic cell death [4,5]. Thus, caspase-3 is
a key effector caspase [4].
It has been recently shown that caspase-3 is subjected to
ubiquitination, followed by 26S proteasome–mediated degra-
dation. Oxidative stress induced caspase-3 polyubiquitination
[6], whereas proteasome inhibitors induced accumulation of
caspase-3 subunits [7] and enhanced apoptosis induced by
overexpression of pro–caspase-3 [8]. Furthermore, XIAP, a
RING finger antiapoptosis protein, was found to bind to rev-
caspase-3 [9], an artificially active caspase-3 generated by
rearranging small subunits (p12) to precede the large subunit
(p20), with capability for autocatalytic processing to active form
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[10]. After binding, intrinsic ubiquitin (Ub) ligase activity of
XIAP promoted the ubiquitination and degradation of rev-
caspase-3 and protected cells from apoptosis [9]. However,
XIAP did not bind to the native inactive form of caspase-3,
pro–caspase-3 [9]. Moreover, cIAP-2, another RING finger
antiapoptosis protein with intrinsic E3 ligase activity, promoted
in vitromonoubiquitination of caspase-3 [11]. Monoubiquitina-
tion or diubiquitination of caspase-3 subunits p17 and p12 was
seen after proteasome inhibitor treatment of transfected cells
[7]. Thus, it appears that caspase-3 is targeted by the Ub
pathway for degradation. However, it is still largely unknown
how the stability of native inactive form of caspase-3 (pro–
caspase-3) is regulated and by which E3 Ub ligase.
Ubiquitination of a target protein involves a well-defined
multistep reaction catalyzed by a Ub-activating enzyme (E1),
a Ub-conjugating enzyme (E2), and a Ub ligase (E3). Skp1–
cullin–F-box protein (SCF) complexes are the largest family
of E3 Ub ligases that ubiquitinate a variety of regulatory
proteins for 26S proteasome degradation. SCF complexes
consist of Skp1, cullin/Cdc53, an F-box protein, and a RING
finger protein SAG/ROC/Rbx/Hrt [12,13]. A recent crystal
structure of the SCF complex revealed that cullin-1 acts as
a scaffold protein, which, at its N-terminus, binds to the
Skp1–F-box complex and, at its C-terminus, binds to ROC/
Rbx that recruits E2 [14]. The substrate specificity of the SCF
complex is determined by F proteins that bind to Skp1 and
cullins through its F-box domain and to substrates through its
WD or LRR domain [14,15]. The large number of F-box pro-
teins found in the human genome [16] suggests that SCF E3
Ub ligases would play a major role in the regulation of a
variety of biologic processes.
We have previously cloned and characterized a redox-
inducible gene, sensitive to apoptosis gene (SAG) [17]. SAG
was found to be essential in yeast growth [18], to promote
cell growth under serum-starved conditions [19,20], and to
inhibit reactive oxygen species (ROS)– induced apoptosis
both in in vitro cell culture models [17] and in in vivo mouse
brain and rat cardiomyocyte ischemia/reperfusion models
[21,22]. The antiapoptotic function of SAG was mediated,
at least in part, through its antioxidant activity by metal
ion binding and free radical scavenging, which inhibited
ROS-induced cytochrome c release and caspase activa-
tion [17,23]. Because SAG is the second family member of
ROC1/Rbx1, which activates SCF E3 Ub ligase activity
through neddylation of cullins and recruitment of E2 [24], we
sought to explore a ligase-associated mechanism of SAG
apoptosis inhibition. We report here that SAG and its family
member ROC1 which also showed antiapoptotic activity [13],
bound to pro–caspase-3 most likely through the F-box
protein b-transducin repeat-containing protein (b-TrCP).
SAG/ROC1–SCFb-TrCP E3 ligase promoted ubiquitination
of pro–caspase-3 in vitro and induced degradation of either
exogenously expressed pro–caspase-3 or endogenous pro–
caspase-3. However, siRNA silencing of SAG, ROC1, or
b-TrCP increased the endogenous levels of pro–caspase-3
and sensitized cancer cells to anticancer agents, etoposide,
or TNF-related apoptosis-inducing ligand (TRAIL) through
caspase-3 activation.
Materials and Methods
Cell Culture, DNA Transfection, and Drug Treatment
The human kidney cell line 293, the breast carcinoma line
MCF7, and the cervical carcinoma line HeLa were grown in
DMEM supplemented with 10% fetal bovine serum. Cells
were subcultured into 100-mm dishes 16 to 24 hours before
transfection to reach 90% confluency. DNA transfection was
conducted using Lipofectamine 2000 reagent (InVitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
For drug treatment, after 24 to 36 hours of transfection, cells
were exposed to a proteasome inhibitor MG132 (10 mM)
for 16 hours, to etoposide (25 mM) for 24 hours, or to TRAIL
(50 ng/ml) for 8 hours. Cell viability was determined by trypan
blue exclusion assay. For half-life determination, MCF7 cells
were cotransfected with pro–caspase-3 and b-TrCP1 or
b-TrCP2 or their F-box–deleted mutants, along with pcDNA3
vector control. Twenty-four hours posttransfection, cells were
treated with cycloheximide (CHX; 10 mg/ml) and harvested at
various time points, then subjected to Western blot analysis.
Western Blot Analysis and Immunoprecipitation (IP)
Cell pellets were lysed in a Triton lysis buffer (20mMTris–
HCl pH 8.0, 150mMNaCl, 1% Triton, 5 mMEGTA, and 5mM
EDTA) with a freshly added protease inhibitor tablet for 1 hour
on ice, followed by a 30-minute centrifugation. Supernatants
were measured for protein concentration using Bio-Rad
protein assay reagent (Bio-Rad, Hercules, CA) and subjected
toWestern blot analysis as described [17] using antibodies to
FLAG tag, HA tag, b-actin (Sigma, St. Louis, MO), caspase-3
(Santa Cruz Biotechnology, Santa Cruz, CA), and Myc tag
(Bethyl Laboratories, Montgomery, TX). For IP, cell lysates
were precleaned with protein A/G beads, then immunopreci-
pitated with bead-conjugated goat anti–caspase-3 antibody
(Santa Cruz Biotechnology), anti-FLAG antibody, or anti-HA
antibody, with preimmuno IgG as negative control. Immuno-
precipitates were washed with Triton lysis buffer three to four
times and subjected to Western blot analysis.
Construction of Pro–Caspase-3 Mutants
The Myc tag pro–caspase-3 and its four deletion mutants
were derived by polymerase chain reaction (PCR) using wild-
type pro–caspase-3 as template [25]. Primer sequences for
wild type are Casp3-05 (5V-GGATCCGCCACCATGGAGAA-
CACTGAAAAC-3V) and Casp3-06 (5V-GGTACCGTGA-
TAAAAATAGAGTTC-3V); for mutant-1 (MT1; p20, subunit,
AA 1–175) are Casp3-05 and Casp3-08 (5V-GGTACCGTCT-
GTCTCAATGCCACAG-3V); for mutant-2 (MT2; p12, small
subunit, AA 175–277) are Casp3-07 (5V-GGATCCGCCAC-
CATGAGTGGTGTTGATGATGAC-3V) and Casp3-06; for
mutant-3 (MT3; AA 39–277) are Casp3-09 (5V-GGATCCGC-
CACCATGGATTATCCTGAGATGGGTTTATG-3V) and
Casp3-06; and for mutant-4 (MT4; dNdC, AA 39–175) are
Casp3-09 and Casp3-08. PCR products were first subcloned
into TA vector, then into pcDNA3.1/Myc-His vector, followed
by sequencing confirmation. The resulting constructs would
express pro–caspase-3, or its deletion mutants with Myc
epitope and His tag at the C-terminus.
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Preparation of ROC1–SCF-TRCP1 Complex
Hi-5 cells were maintained in HfQ SFX insect cell medium
(Perbio, Belgium) with 1 penicillin–streptomycin (Cellgro,
Herndon, VA) at 25jC. Baculoviral expression constructs of
ROC-1, HA-Cul1, HIS-Skp1, and FLAG-b-TRCP1 were
titered for optimal expression in Hi-5 cells. Hi-5 cells were
grown to approximately 50% confluence on 100-mm plates
before infection. The constructs were infected separately for
maximum expression. After 4 days, the cells were then har-
vested and centrifuged at 3000 rpm for 10 minutes at 4jC.
The medium was removed, and the cells were washed once
in 20 ml of PBS and centrifuged a second time. The pellets
were lysed by vigorous pipetting and repetitive freeze–thaw
in nickel lysis buffer (50 mM NaH2PO4 pH 8, 300 mM NaCl,
and 10 mM imidazole) with phenylmethylsulfonyl fluoride
and pepstatin A. Lysates were spun at high speed for 10 min-
utes to remove debris, and the supernatants from each
construct were combined. The combined lysis was rotated
at 4jC for 2 hours, and then 1 ml of clean 50% Ni-NTA
agarose bead slurry (Qiagen, Valencia, CA) was added.
The bead was rotated for an additional 2 hours. The lysate
was then centrifuged at 6000 rpm for 3 minutes, and the
supernatant was removed. Bead pellet was resuspended
in Ni wash buffer (50 mM NaH2PO4 pH 8, 300 mM NaCl,
and 20 mM imidazole) and loaded onto an elution column
where it was washed with 1 ml of Ni wash buffer for six times.
Proteins were then eluted in 200 ml of a Ni elution buffer
(50 mM NaH2PO4 pH 8, 300 mM NaCl, and 250 mM imid-
azole) for six fractions. The fractions were pooled into two
groups according to concentration and dialyzed in 4 l of Buffer
C-100 (20 mM Tris–Cl pH 7.5, 100 mM KCl, 0.2 mM EDTA,
and 20% glycerol) for at least 2 hours. The fractions were run
on sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) and checked by Western blot analy-
sis using polyclonal anti-ROC1 (Neomarkers, Fremont, CA),
monoclonal 12CA5 anti-HA (generated in Lu Laboratory),
monoclonal anti-FLAG (Sigma), and monoclonal anti-
HIS (Covance, Princeton, NJ) antibodies to detect separate
complex components.
Preparation of SAG–SCF-TRCP1 Complex
The SAG–SCFb-TRCP1 complex was prepared as above,
except for the SAG, which was purified separately before
complex reconstitution. GST-SAG was grown in LB broth to
log phase and induced using 0.4 mM IPTG (Fisher, Chino,
CA). Bacteria were harvested after 6 hours at 37jC, centri-
fuged at 35,000 for 20minutes, and lysed in 20ml of bacterial
lysis buffer (1 PBS, 10% glycerol, and 0.1% NP-40) by
French press. The lysate was spun at high speed for 10 min-
utes to remove cell debris and then incubated for 5 minutes
at room temperature with 500 ml of GSH slurry. After bind-
ing, GST-SAG beads were washed thrice in GSTwash buffer
(1 PBS, 10% glycerol, and 500 mM NaCl) and eluted using
5 mM reduced glutathione (Sigma). The fractions were
dialyzed using the same conditions as above, and the pro-
tein was examined for concentration and purity using SDS-
PAGE followed by Coomassie staining. The fraction with
the highest purity was combined with insect lysates ob-
tained by the same procedure as above. After the steps noted
above, purified complex fractions were rebound to GSH
beads, washed twice in lysis buffer (50 mM Tris pH 7.5,
5 mM EDTA, 150 mM NaCl, and 0.5% NP-40), and diluted
to 50% slurry. In vitro ubiquitination was preformed on the
same day to maintain complex activity.
Expression and Purification of FLAG-Tagged
Pro–Caspase-3
Pro–caspase-3 substrate was prepared from an IPTG-
inducible bacterial construct following a similar induction and
preparation protocol as noted above for GST-SAG. After
French press and centrifugation, 40 ml of 50% monoclonal
FLAG M2-conjugated affinity agarose bead slurry (Sigma)
was added to the clarified lysate and incubated at 4jC for
4 hours. The beads were washed twice in 1 ml of lysis buffer
(50mMTris–Cl pH 7.5, 150mMNaCl, 5mMEDTA, and 0.5%
NP-40) and twice in 1 ml of SNNTE lysis buffer (50 mM Tris–
Cl pH 7.4, 500 mM NaCl, 5 mM EDTA, 5% sucrose, and 1%
NP-40). They were then eluted using 630-ml fractions of
0.1 mg/ml FLAG peptide. Their concentration was then de-
termined by pro–caspase-3 Western blot analysis, and
samples of similar concentration were dialyzed in 4 l of Buffer
C-100 for 2 hours at 4jC. Five microliters of these final
fractions was used per sample for the assays.
In Vitro Ubiquitination
SAG/ROC1–SCFb-TRCP1–mediated in vitro ubiquitination
assay was performed as described previously [26]. Pro–
caspase-3 in vitro ubiquitination assay was carried out in
40 ml of a reaction mixture containing 50 mM Tris–HCl
(pH 8.0), 5 mM MgCl2, 0.5 mM dithiothreitol, 2 mM NaF,
3 mM okadaic acid, 400 ng of Uba-1 (Boston Biochem, Cam-
bridge, MA), 400 ng of UbcH3 (Boston Biochem), 1000 ng of
HAUb, 5mMATP (AmershamBiosciences, Piscataway, NJ),
1.5 mM ATPg (Fisher ICN, Chino, CA), and 20 ml of purified
ROC1–SCFb-TRCP1 complex or 8 ml of SAG–SCFb-TRCP1
bead slurry. Five microliters of purified FLAG-tagged pro–
caspase-3 was used in each reaction. The mixture was in-
cubated at 37jC for 1.5 hours and analyzed afterward by
SDS-PAGE followed by Western blot analysis. Ubiquitinated
pro–caspase-3 was detected by immunoblot using mono-
clonal anti/pro–caspase-3 antibody (BD Transduction Labo-
ratory, San Jose, CA).
siRNA Silencing of SAG, ROC1, or -TrCP
Plasmid-based hairpin RNA were used to silence SAG,
ROC1, or b-TrCPs. The pU6pro vector (a kind gift from
Dr. David L. Turner, University of Michigan, Ann Arbor, MI)
was used [27] as detailed previously (http://sitemaker.umich.
edu/dlturner.vectors). Two sets of siRNA template oligonu-
cleotides were synthesized (InVitrogen) to silence SAG. For
psiSAG-1, the sequences are iSAG-1-1 (5V-TTTGAAGGC-
TTCTTAGCGCAGTTGTTCAGAGCCAAGAGGCTCTGAA-
CAACTGCGCTAAGAAGCCTTTTTT-3V) and iSAG-1-2 (5V-
CTAGAAAAAGGCTTCTTAGCGCAGTTGTTCA -
AGAGCCTCTTGGCTCTGAACAACTGCGCTAA-
GAAGCCTT-3V). For psiSAG-2, the sequences are iSAG-2-1
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(5V-TTTGAACAAGAGGACTGTGTTGTGGTCTGGCAA-
AGAGCCAGACCACAACACAGTCCTCTTGTTTTT-3V) and
iSAG-2 -2 (5 V-CTAGAAAAACAAGAGGACTGTG-
TTGTGGTCTGGCTCTTGCCAGACCACAACACAGT-
CCTCTTGTT-3V). For psiROC1, the sequences are iROC1-1
(5 V-TTTGAAGACTTCTTCCATCAAGCTTCAAGA-
AGAAGCTTGATGGAAGAAGTCTTTTT-3V) and iROC1-2
(5V-CTAGAAAAAGACTTCTTCCATCAAGCTTCTCTT-
TGAAGCTTGATGGAAGAAGTCTT-3V). For psi-b-TrCPs
(silencing both b-TrCP1 and b-TrCP2), the sequences are
ib-TrCP01 (5V-TTTGAAGTGGAATTTGTGGAACATCTT-
TCAAGAGAAGATGTTCCACAAATTCCACTTTTT-3V) and
ib-TrCP02 (5 V-CTAGAAAAAGTGGAATTTGTGGAA-
ACATCTTCTCTTGAAGATGTTCCACAAATTCCACTT-3V).
The control psiCont sequences are iCont01 (5V-TTTG-
AT TGTATGCGATCGCAGACTTCAAGAGAAG -
TCTGCGATCGCATACAATTTTT-3V) and iCont02 (5V-
CTAGAAAAATTGTATGCGATCGCAGACTTCTCTT-
TGAAGTCTGCGATCGCATACAAT-3V). The cohesive ends
of restriction enzymes BbsI (TTTG) and XbaI (CTAG) are
italicized. Annealed synthetic primers were ligated into the
pU6pro vector predigested with BbsI and XbaI. Recombinant
plasmids of psiSAG-1, psiSAG-2, psi-b-TrCP, and psiCont
were confirmed by DNA sequencing. The plasmids were
transfected into HeLa cells using Lipofectamine 2000 reagent
(InVitrogen), and silencing of endogenous SAG, ROC1, or
b-TrCP1 was determined using antibodies against SAG,
ROC1, or b-TrCP1 (Zymed, Carlsbad, CA), respectively.
Caspase-3 Activity Assay
Caspase-3 activity was measured by a fluorogenic cas-
pase-3 assay using Ac-DEVD-AFC (Biomol, Plymouth meet-
ing, PA) as substrate, as described previously [28]. Briefly,
HeLa cells were seeded in 24-well plate 1 day before Lip-
ofectamine transfection of siRNA plasmids targeting SAG
and ROC1, along with a control plasmid with random se-
quence. Thirty-six hours posttransfection, cells were treated
with either etoposide (25 mM) for 24 hours or with TRAIL (50
ng/ml) for 8 hours. Cells were then lysed in a lysis buffer (1.67
mM Hepes pH 7.4, 7 mM KCl, 0.83 mM MgCl2, 0.11 mM
EGTA, 0.11 mM EDTA, and 0.57% CHAPS) for 30 minutes,
followed by centrifugation at 14,000 rpm for 15 minutes.
Supernatants were collected and incubated with a caspase-
3 activity assay buffer (120 mM Hepes pH 7.4, 630 mM
sucrose, 0.25% CHAPS, 10 mM DTT, and 50 mM Ac-
DEVD-AFC fluorescent substrate). The plates were read 2
hours after the addition of Ac-DEVD-AFC substrate at 400 nm
(excitation) and 505 nm (emission) in a TECAN Ultra fluores-
cence reader (TECAN, Rancho Santa, CA).
Results
SAG or ROC1 Bound to Endogenous Pro–Caspase-3
Although it has been known that the active form of
caspase-3 is ubiquitinated by XIAP E3 Ub ligase and that
inactive pro–caspase-3 appears to be degraded through
the ubiquitination and 26S proteasome pathway [6–9], it is
completely unknown which E3 Ub ligase mediates the ubiq-
uitination of the inactive prozymogen form of caspase-3
(pro–caspase-3). In an attempt to elucidate the E3 Ub
ligase–associated mechanism by which SAG protects cells
from apoptosis [17,21,22,29], we sought to determine
whether pro–caspase-3 (32 kDa) is a substrate of SAG–
SCF E3 Ub ligase. We first measured whether SAG physi-
cally bound to endogenous pro–caspase-3. FLAG-tagged
SAG was transiently transfected into 293 cells. Endogenous
pro–caspase-3 was immunoprecipitated with goat anti–
caspase-3 antibody or with goat IgG as control, followed by
Western blot analysis using anti-FLAG antibody to determine
whether transfected SAG was coprecipitated with endoge-
nous pro–caspase-3. Indeed, as shown in Figure 1A, FLAG-
taggedSAG (15 kDa) was detected inSAG-transfected—but
not control vector–transfected—cells in immunoprecipitates
by pro–caspase-3 antibody, but not by control IgG. We next
determined whether the SAG family member ROC1 would
also bind to endogenous pro–caspase-3. HA-tagged ROC1
was transiently transfected into 293 cells. Again, endogenous
pro–caspase-3 was immunoprecipitated by anti–caspase-3
antibody or control IgG, followed by Western blot analysis
using anti-HA antibody to detect ROC1, if two proteins bind
together. As shown in Figure 1B, ROC1 can be detected in
immunoprecipitates pulled down by anti–caspase-3 anti-
body, but not by control IgG. Expression of both SAG and
ROC1 was detected by direct Western blot analysis shown
at the bottom panels (Figure 1, A and B). Thus, it appears
that both SAG and its family member ROC1 bound to pro–
caspase-3 in vivo.
F-box Protein -TrCP1 or -TrCP2 Bound
to Pro–Caspase-3 at Its N-terminus
Based on the published crystal structure of the SCF
complex [14], the binding of SAG/ROC to protein substrates
such as pro–caspase-3 has to be mediated by an F-box
protein. We therefore determined which F-box protein would
mediate SAG/pro–caspase-3 binding. Because, like SAG,
b-TrCP was also involved in the survival of cancer cells [30],
it is a putative candidate. Before confirming b-TrCP/pro–
caspase-3 binding, we first determined whether SAG
bound to b-TrCPs. It has been well-established that ROC1
is included in the SCFb-TrCP complex [31,32], and we know
that SAG bound to cullin-1 [18], which acts as a scaffold
protein to bridge SAG and Skp1–F-box protein [14]. HA-
tagged b-TrCP2 was cotransfected with FLAG-tagged SAG
into 293 cells. SAG was pulled down with anti-FLAG anti-
body, along with preimmune IgG control, and b-TrCP2 was
detected by IB using anti-HA antibody in immunoprecipitates,
pulled down by FLAG (SAG), but not by control IgG (Fig-
ure 1C), indicating in vivo SAG–b-TrCP2 binding. Similarly,
HA-tagged SAG was cotransfected into 293 cells with
FLAG-tagged b-TrCP1, and SAG was detected in b-TrCP
immunoprecipitates by anti-FLAG antibody but not in con-
trol IgG immunoprecipitates, (Figure 1D), again indicating
in vivo binding of SAG–b-TrCP1. Expressions of cotrans-
fected SAG, ROC, or b-TrCPs were shown at the two
bottom panels by direct Western blot analysis.
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Having confirmed SAG–Cul1–b-TrCP binding, we deter-
mined whether b-TrCP1 or b-TrCP2 directly bound to pro–
caspase-3.HA-tagged b-TrCP2was transfected into293cells
and was detected in pro–caspase-3 immunoprecipitates,
pulled down by anti–caspase-3 antibody, but not by pre-
immune IgG (Figure 2A). The bottom panel showed that
HA-b-TrCP2 was expressed at an equal level in both trans-
fections. Similarly, FLAG-tagged b-TrCP1 or its F-box dele-
tion mutant b-TrCP1DF was transfected into 293 cells and
was again detected in immunoprecipitates, pulled down by
anti–caspase-3 antibody (Figure 2B). Expressions of b-
TrCP1 and b-TrCP1DF were shown at the bottom panel. All
these experiments indicated that, indeed, b-TrCP1 or b-
TrCP2 bound to pro–caspase-3 in vivo and that the binding
of SAG/pro–caspase-3 is most likely mediated through
F-box protein b-TrCP1 or b-TrCP2.
It has been well established that b-TrCP binds to its sub-
strate through its WD40 repeats at the C-terminus [33–35].
We therefore mapped the region in caspase-3 to which
b-TrCP binds. Wild-type pro–caspase-3 and its four deletion
mutants with C-terminal Myc tag were derived (Figure 2C):
MT1, p20, the large subunit (AA 1–175);MT2, p12, the small
unit (AA 176–277); MT3, dN (AA 39–277); and MT4, dNdC
(AA 39–175). All four mutants, along with wild-type pro–
caspase-3 (WT), were transiently transfected into 293 cells,
and their expressions were detected byWestern blot analysis
with Myc-tag antibody. The levels of expression from high to
low were WT, MT1, and MT4, in that order. No expression of
MT2 andMT3was detectable (data not shown).We therefore
focused our attention on the potential binding of b-TrCP to
MT1 and MT4. The 293 cells were transiently cotransfected
with HA-b-TrCP2 in a combination of WT, MT1, or MT4, re-
spectively, and then subjected to directWestern blot analysis.
As shown in Figure 2D, HA-b-TrCP2 was expressed equally
well among all four transfections (80 mg of cellular protein was
loaded from each transfection). However, the expression
varied among WT and its mutants. As shown in Figure 2E,
WT was expressed at the highest level (20 mg of cellular
protein loaded), followed by p20 (60 mg of protein loaded)
and dNdC (100 mg of protein loaded). Based on these dif-
ferent levels of expression, the amount of total cellular protein
used for IPwas 200 mg forWT, 600 mg for p20/MT1 or pcDNA3
vector control, and 2.5 mg for dNdC/MT4. Following IP with
HA antibody, along with preimmune IgG as negative control,
potential b-TrCP2 binding to pro–caspase-3 was detected
by Western blot analysis using anti-Myc-tag antibody. As
shown in Figure 2F, a strong WT band was visualized when
anti-HA antibody (lane 2), but not preimmuno-IgG (lane 3),
was used for IP, indicating that WTstrongly binds to b-TrCP2,
consistent with the data shown in Figure 2A. A relatively weak
Figure 1. SAG or ROC1 bound to endogenous pro–caspase-3 in 293 cells. Human 293 cells were transiently transfected with pcDNA3 vector control, FLAG-
tagged SAG (A), or HA-tagged ROC1 (B), using Lipofectamine 2000. Cell lysates were prepared after transfection and subjected to IP with anti – caspase-3
antibody or control IgG, as indicated after preclearing with protein A/G-plus agarose beads, followed by immunoblotting using anti-FLAG antibody or anti-HA
antibody, respectively. The bottom panel shows direct immunoblotting using whole-cell extract with anti-FLAG or anti-HA antibody, respectively, to show that
transfected SAG or ROC1 was expressed in 293 cells. (C) SAG–-TrCP2 binding. Human 293 cells were transiently cotransfected with HA--TrCP2 and FLAG-
SAG or pcDNA3 vector control. After transfection, cell lysates were prepared and subjected to IP using anti-FLAG antibody or control IgG, as indicated after
preclearing with protein A/G-plus agarose beads, followed by immunoblotting with anti-HA antibody (top). Expression of transfected -TrCP2 (middle) and SAG
(bottom) was detected by direct immunoblotting of whole-cell extract. (D) SAG–-TrCP1 binding. Human 293 cells were cotransfected with FLAG--TrCP1 and
HA-SAG or pcDNA3 vector control. Cell lysates were prepared and subjected to IP using anti-FLAG antibody or control IgG, as indicated after preclearing with
protein A/G-plus agarose beads, followed by immunoblotting using anti-HA antibody (top). Expression of transfected -TrCP1 (middle) and SAG (bottom) was
detected by direct immunoblotting of whole-cell extract.
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binding of p20/MT1 to b-TrCP2 was detected (lane 4), con-
sistent with its relatively low expression in comparison with
WT. No b-TrCP2 binding was detected with pcDNA3-Myc
vector control (lane 1), nor with dNdC mutant, even though
4-fold to 12-fold more input cellular proteins were used for
IP to compensate for a lower expression (lane 5). The results
suggested that the p12 subunit at the C-terminus is dispens-
able for b-TrCP2 binding, whereas the first 38 amino acids
at the N-terminus are required for b-TrCP2 binding.
-TrCP1 or -TrCP2 Expression Shortened the Protein
Half-Life of Pro–Caspase-3
We next determined whether b-TrCPs/pro–caspase-3
binding would lead to degradation of pro–caspase-3. For
simplicity, we used MCF7 cells, a human breast cancer cell
line that lacks endogenous pro–caspase-3 as a result of a
47-bp deletion in the exon 3 of the gene [36,37]. MCF7 cells
were cotransfected with pro–caspase-3 and an increasing
amount of b-TrCP1, along with the control plasmid pcDNA3.
Cell lysates were prepared 38 hours posttransfection and
subjected to Western blot analysis using anti–caspase-3
antibody. As shown in Figure 3A, pro–caspase-3 level de-
creased as the amount of b-TrCP1 increased, indicating a
dose-dependent degradation of pro–caspase-3 by b-TrCP1.
Having established this, we next determined the poten-
tial shortening of the protein half-life of pro–caspase-3
by b-TrCPs. MCF7 cells were cotransfected with pro–
caspase-3, along with b-TrCP1, its dominant-negative form
b-TrCP1DF, or the empty vector control pcDNA3. Following
24 hours of transfection, cells were treated with CHX to block
new protein synthesis. Samples were collected at various
time points after CHX treatment and subjected to Western
Figure 2. -TrCPs bound to pro–caspase-3 require prodomain. (A) -TrCP2 bound to endogenous pro–caspase-3. Human 293 cells were transiently transfected
with HA--TrCP2 or pcDNA3 vector control. Cell lysates were prepared and subjected to IP using anti –caspase-3 antibody or preimmune IgG, as indicated after
preclearing with protein A/G-plus agarose beads, followed by immunoblotting using anti-HA antibody (top panel). A direct immunoblotting analysis of whole-cell
extract was performed using anti-HA antibody to show -TrCP2 expression (bottom). (B) -TrCP1 bound to endogenous pro–caspase-3. Human 293 cells were
transiently transfected with pcDNA3 vector control (lane 1), FLAG--TrCP1 (lane 2), and FLAG-b-TrCP1DF (lane 3). Cell lysates were prepared and subjected to IP
using anti – caspase-3 antibody followed by Western blot analysis with anti-FLAG antibody (top), or whole-cell extracts were directly subjected to Western blot
analysis to show expression of FLAG--TrCP1 and FLAG-b-TrCP1DF (bottom). Requirement of prodomain for -TrCP-pro–caspase-3 binding. (C) Bar graphic
presentation of pro–caspase-3 mutants. (D–F) Human 293 cells were cotransiently transfected with HA--TrCP2 in combination with WT pro–caspase-3 or its
deletion mutants, along with the vector control. Thirty-eight hours posttransfection, cells were harvested and subjected to Western blot analysis (D and E) using
indicated antibodies or IP, followed by Western blot analysis using myc antibody (F). NB, nonspecific band.
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blot analysis to determine the pro–caspase-3 half-life. As
shown in Figure 3B, with densitometric qualification data
presented in Figure 3C, the protein half-life for transfected
pro–caspase-3 in MCF7 cells is about 5.5 hours. Cotrans-
fection with b-TrCP1 shortened the half-life to 3 hours,
whereas cotransfection with b-TrCP1DF extended the half-
life to > 7 hours. Similar results were observed when b-TrCP2
or b-TrCP2DF was cotransfected with pro–caspase-3 (data
not shown). The results suggested that b-TrCP1 or b-TrCP2
bound to pro–caspase-3 and shortened its half-life likely
by promoting its degradation. In contrast, b-TrCP1DF or
b-TrCP2DF that bound to pro–caspase-3 as well (Figure 2B),
but not to other components of SCF ligase [38], acted in a
dominant-negative manner to block pro–caspase-3 degrada-
tion, thus extending its half-life.
SAG/ROC–SCF-TrCP E3 Ligase Promoted
Pro–Caspase-3 Ubiquitination In Vitro
We next established an in vitro ubiquitination assay to
determine whether SAG/ROC–SCF E3 Ub ligase would
promote ubiquitination of pro–caspase-3. We first purified
ROC1–SCF or SAG–SCF complexes containing HA-Cul1,
His-Skp1, and FLAG-b-TrCP1, plus either ROC1 or GST-
SAG, as described in Materials and Methods section. These
complexes were used as E3 in an in vitro ubiquitination
reaction with purified FLAG-pro–caspase-3 as substrate.
As shown in Figure 4A, several slow-migrating bands ranging
from 54 to 100 kDa, reflecting ubiquitinated pro–caspase-3,
were detected only when the reaction mixture contained Ub,
E1, E2, ROC1–SCF, and pro–caspase-3 (lane 4). Omission
of E1, E2, E3, and Ub (lane 1); E3 and Ub (lane 2); E1 and
E2 (lane 3); or pro–caspase-3 (lane 5) all failed to detect it.
Likewise, SAG–SCF E3 Ub ligase also induced ubiquitina-
tion of pro–caspase-3 in the presence of Ub, E1, and E2
(left lane), which is not detected in the absence of pro–
caspase-3 (right lane), which serves as negative control. It
is worth noting that pro–caspase-3 ubiquitination by SAG–
SCF was not as pronounced as that by ROC1–SCF. This
may reflect a stoichiometric difference during purification
because ROC1–SCF was expressed and copurified from
baculovirus as a complex, whereas in the SAG–SCF com-
plex, GST-SAG was prepared from bacterial source and
mixed with other SCF components prepared from baculo-
virus. Nevertheless, the results indicated that, indeed, pro–
caspase-3 could be ubiquitinated by SAG/ROC–SCF E3 Ub
ligase using components purified in vitro.
SAG–SCF-TrCP E3 Ub Ligase Regulated the Endogenous
Level of Pro–Caspase-3
We have now shown that b-TrCP1 cotransfection short-
ened the protein half-life of pro–caspase-3 and that SAG–
SCFb-TrCP E3 ubiquitin ligase promoted the ubiquitination of
pro–caspase-3 in vitro. We next determined whether SAG/
ROC–SCFb-TrCP E3 ubquitin ligase can decrease the steady-
state levels of endogenous pro–caspase-3. The 293 cells
were transiently cotransfected with plasmid expressing Ub, in
combination with plasmids expressing pcDNA3 control,
b-TrCP1, SAG, ROC1, SAG + b-TrCP1 + Cul1 + Skp1, or
ROC1 + b-TrCP1 + Cul1 + Skp1, respectively. Cells were
lysated after transfection and subjected to direct Western
blot analysis using anti–caspase-3 antibody. As shown in
Figure 5A (top panel ), compared to the vector control (lane 1),
Figure 3. -TrCPs shortened the protein half-life of pro–caspase-3. (A) -TrCP1 induced a dose-dependent reduction of pro–caspase-3. Pro–caspase-3–null
MCF7 cells were cotransfected with FLAG-pro–caspase-3 and an increasing amount of -TrCP1. Thirty-eight hours posttransfection, cell lysates were prepared and
subjected to direct Western blot analysis using anti – caspase-3 antibody, as well as anti-actin antibody as loading control. (B and C) -TrCP1 shortened—but its
dominant-negativemutant extended—the pro–caspase-3 half-life. MCF7 cells were transiently cotransfected with FLAG-pro–caspase-3, along with pcDNA3 vector
control, -TrCP1, or b-TrCP1DF, as indicated. Twenty-four hours posttransfection, cells were treated with CHX (10 g/ml) for indicated time periods up to 7 hours
and harvested. Cell lysates were prepared and subjected toWestern blot analysis with anti-FLAG antibody or anti –-actin antibody as loading control. Densitometric
quantification of pro–caspase-3 levels was shown in (C), with value at 0 hour after CHX treatment arbitrarily set to 1, on which the fold change was calculated.
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transfection with b-TrCP1 (lane 2), SAG (lane 3), and ROC1
(lane 4) alone did not significantly change the endogenous
level of pro–caspase-3. However, when SAG or ROC1 was
cotransfected with other components of SCF (lanes 5 and 6),
endogenous pro–caspase-3 was significantly reduced to a
nearly undetectable level, indicating a requirement of all SCF
components in promoting the degradation of endogenous
pro–caspase-3 in 293 cells. The lack of detection of caspase-
3 subunits p20 and p12 (lanes 5 and 6) excluded the
possibility that the decrease of pro–caspase-3 level is due
to SAG/ROC–SCF–induced caspase-3 activation. Because
b-TrCP1 is significantly stabilized in the presence of other
SCF components (compare lane 2 vs lanes 5 and 6, middle
panel ), it raised a possibility that b-TrCP1 might be the rate-
limiting component in SAG/ROC–SCF–mediated pro–
caspase-3 degradation. In contrast, replacement of b-TrCP1
with its F-box deletion mutant b-TrCP1DF in the SAG–SCF
complex completely abolished its pro–caspase-3–degrading
activity (cf. lanes 2 and 3 vs lane 1, Figure 5A, bottom panel ),
suggesting that b-TrCP1 is the major—if not the only—F-box
protein that mediated pro–caspase-3 degradation by SAG–
SCF E3 Ub ligase, assuming that other F-box proteins are
expressed in a sufficient amount in 293 cells. To further
determine whether SAG–SCF E3–induced degradation of
endogenous pro–caspase-3 is a proteasome-dependent
process, SAG–SCFb-TrCP– transfected cells were treated
with MG132, a proteasome inhibitor (lane 5). Indeed,
SAG–SCFb-TrCP ligase–induced reduction of endogenous
pro–caspase-3 (Figure 5A, bottom panel, lane 2 vs lane 1)
was completely blocked by MG132 (lane 5 vs lane 4, com-
pared to lane 2 vs lane 1), indicating that pro–caspase-3
degradation is mediated by proteasomes.
Because overexpression of SAG/ROC1–SCFb-TrCP E3
ligase reduced the steady-state level of endogenous pro–
caspase-3, we next determined whether siRNA silencing of
SAG, ROC1, or b-TrCP could cause the accumulation of
endogenous pro–caspase-3. HeLa cells were transiently
transfected with plasmid-based hairpin RNA specifically tar-
geting SAG, ROC, or b-TrCPs (both b-TrCP-1 and b-TrCP-2).
The endogenous level of SAG, ROC1, or b-TrCP1 was mea-
sured by antibodies to each protein. As shown in Figure 5B
(bottom panel ), compared to control plasmid with random
targeting sequence (lane 1), two psiSAG plasmids (lane 2 for
psiSAG-1 and lane 3 for psiSAG-2) reduced endogenous
SAG level up to five-fold. Likewise, psiROC1-1 (lane 5 ), but
not control psiCont (lane 4), completely silenced endogenous
ROC1 expression. As a result of SAG or ROC1 silencing,
endogenous pro–caspase-3 level increased two-fold to
four-fold (Figure 5B, top panel ). Likewise, siRNA silencing
of b-TrCP1 up to three-fold caused a two-fold accumulation
of pro–caspase-3 (Figure 5C). In summary, when over-
expressed, SAG/ROC1–SCFb-TrCP E3 ligase promoted a
proteasome-dependent degradation of endogenous pro–
caspase-3, whereas silencing of SAG, ROC1, or b-TrCPs in-
duced its accumulation. Thus, it appears that pro–caspase-3
is a substrate of SAG–SCFb-TrCP E3 Ub ligase.
siRNA Silencing of SAG, ROC1, or -TrCPs Caused an
Increased Activity of Caspase-3 on Activation and Sensitized
Cancer Cells to Apoptosis Induced by Anticancer Agents
We have previously shown that SAG inhibited apoptosis
in several cancer cell lines, as well as in two ischemia/
reperfusion models, both in vitro and in vivo [17,21,22]. Here
we showed that SAG–SCF promoted pro–caspase-3
Figure 4. Pro–caspase-3 ubiquitination by SAG/ROC–SCF E3 Ub ligase. (A) ROC1–SCF-TrCP E3 ligase. Bacterially expressed and purified FLAG-tagged pro–
caspase-3 was combined with Ub, Uba1 (E1), UbcH3 (E2), and E3, ROC1–SCFTrCP1, in which each component was individually expressed in baculovirus and
copurified as a four-component complex, as described in Materials and Methods section. Omission of some components was carried out as indicated. Samples were
incubated in the presence of ATP buffer for 1.5 hours at 37jC, run on a 10% to a 15% gradient SDS-PAGE, and blotted with anti-pro–caspase-3 antibody.
*Nonspecific band. HC indicates the heavy chain of IgG. (B) SAG–SCF-TrCP. Bacterially purified FLAG-tagged pro–caspase-3 and GST-SAG were combined with
Ub, Uba1 (E1), Ubc3 (E2), and SCFTrCP1, in which each component was individually expressed in baculovirus and copurified as a three-component complex, as
described in Materials and Methods section. Omission of pro–caspase-3 on the right lane was indicated. Samples were incubated in the presence of ATP buffer for
1.5 hours at 37jC, run on a 10% SDS-PAGE, and blotted with anti/pro–caspase-3 antibody. HC, heavy chain from FLAG affinity purification. *Nonspecific signals.
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Figure 5. Pro–caspase-3 is a substrate of SAG/ROC1–SCF-TrCP E3 ligase. (A) SAG/ROC–SCF-TrCP E3 Ub ligase promoted the degradation of endogenous
pro–caspase-3. Top panel: Human 293 cells were transiently transfected with Ub, along with the pcDNA vector control (lane 1), FLAG--TrCP (lane 2), FLAG-SAG
(lane 3), HA-ROC1 (lane 4), all four components of SAG–SCF E3 Ub ligase (SAG–SCF, SAG + -TrCP1 + Cul1 + Skp1, lane 5), or all four components of
ROC1–SCF E3 ligase (ROC1–SCF; lane 6), respectively. Cell lysates were prepared 38 hours posttransfection and subjected to Western blot analysis with anti –
caspase-3 antibody. The blots were stripped and reprobed with antibodies against FLAG tag for the expression of -TrCP1 (panel 2), SAG (panel 3), HA tag for
ROC1 expression (panel 4), and -actin (panel 2) for loading control. Bottom panel: Proteasomal-dependent degradation of pro–caspase-3 by SAG–SCF-TrCP1
E3 ligase. Human 293 cells were transiently transfected with Ub, along with the pcDNA vector control (lanes 1 and 4), SAG–SCF-TrCP1 (lanes 2 and 5), or SAG–
SCF-TrCP1DF (a substitution of wild-type -TrCP1 with its F-box–deleted mutant; lanes 3 and 6). Twenty-four hours posttransfection, cells were either left untreated
(left panel) or treated with 10 M MG132 (right panel) for 16 hours. Cell lysates were then prepared and subjected to Western blot analysis, with antibodies against
caspase-3 or actin as loading control. (B) siRNA silencing of SAG or ROC1 increased the endogenous level of pro–caspase-3. HeLa cells were transfected with
plasmid-based hairpin RNA designed to silence SAG or ROC1: psiSAG-1 (lane 2) and psiSAG-2 (lane 3), as well as psiROC-1 (lane 5), along with control psiCont
(lanes 1 and 4). Thirty-eight hours posttransfection, cell lysates were prepared and subjected to Western blot analysis using antibodies against caspase-3 (top
panel), actin (middle panel) or SAG (lanes 1–3, bottom panel), or ROC1 (lanes 4 and 5, bottom panel). The value of densitometric quantification after normalization
with -actin for equal protein loading was shown on the bottom of each panel, with control number setting at 1, on which the fold change was calculated. (C) siRNA
silencing of -TrCP1 increased the endogenous level of pro–caspase-3. HeLa cells were transfected with plasmid-based hairpin RNA designed to silence -
TrCP1: -TrCP1-si, along with control psiCont (Cont). Thirty-eight hours posttransfection, cell lysates were prepared and subjected to Western blot analysis using
antibody against caspase-3 (top panel), -TrCP1 (middle), or -actin (bottom). The value of densitometric quantification after normalization with -actin for equal
protein loading was shown on the bottom of each panel, with control number setting at 1 on which the fold change was calculated.
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degradation, as well as its accumulation on SAG silencing.
We next determined whether accumulation of pro–caspase-
3 by siRNA silencing of SAG, ROC1, or b-TrCPs leads to a
higher caspase-3 activity on activation by exposure to its
activator etoposide (mitochondrial pathway) or TRAIL (death
receptor pathway) and whether SAG, ROC1, or b-TrCP
silencing sensitizes cancer cells to these two apoptosis-
inducing agents. HeLa cells were transiently transfected
with psiSAG-2, psiROC1-1, or b-TrCP-si, which was shown
to reduce endogenous SAG, ROC1, or b-TrCP1, respectively
(Figure 5B). Thirty-six hours posttransfection, cells were
treated with DMSO control, etoposide (25 mM), or TRAIL
(50 ng/ml) to induce caspase-3 activation through the mito-
chondrial pathway or the death receptor pathway, respec-
tively. Caspase-3 activity was measured and shown in
Figure 6A. As expected, silencing of SAG, ROC1, or b-TrCPs
did not change the basal activity of pro–caspase-3 (DMSO),
whereas etoposide or TRAIL treatment caused a 50% in-
crease of caspase-3 activity. Significantly, a combination of
the silencing ofSAG, ROC1, or b-TrCPs alone with etoposide
or TRAIL treatment caused a > 100% increase in caspase-3
activity. Consistent with this, a two-fold induction of apoptosis
by etoposide or TRAIL alone was further increased up to
three-fold on the silencing of SAG, ROC1, or b-TrCPs, re-
spectively (Figure 6B). These results demonstrated that the
accumulation of pro–caspase-3 by the silencing of SAG,
ROC1, or b-TrCPs, respectively, translated into a higher
caspase-3 activity on activation and an increased apoptosis
induction on exposure to anticancer agents.
Discussion
SCF E3 Ub ligase is one of the well-defined E3 Ub ligases in
eukaryotes that mainly control cell cycle progression [12].
Recent work has implicated its role in apoptosis regulation as
well. Through F-box protein Fbw7 or Cdc4, SCF E3 ligase
promoted the ubiquitination and degradation of c-Jun, thus
blocking apoptotic JNK signal pathway [39]. However,
through F-box protein b-TrCP, SCF E3 ligase could protect
cells from apoptosis through the ubiquitination and degrada-
tion of InB [38,40], leading to activation of NFnB, an anti-
apoptotic transcription factor that regulates cell survival and
renders cancer cells resistant to chemotherapeutic agents
[41,42]. Importantly, an elevated expression of b-TrCP1 was
found in colon cancers, particularly in those with metastases,
which was associated with the activation of both b-catenin
and NFnB and may contribute to inhibition of apoptosis and
tumor metastasis [43]. Furthermore, an increased level of
b-TrCP1 was found in pancreatic carcinoma cells, which
correlated with constitutive NFnB activation and chemore-
sistance [44]. However, targeting b-TrCP1 through siRNA
silencing or overexpression of dominant-negative mutant
suppressed the growth and survival of human breast cancer
cells [30], consistent with our observation that siRNA silenc-
ing of b-TrCPs sensitized cancer cells to apoptosis induced
by anticancer agents.
In this study, we demonstrated yet another potential
mechanism by which SAG–SCFb-TrCP E3 Ub ligase protects
cancer cells from apoptosis. Through the binding of SAG/
ROC-b-TrCPs with pro–caspase-3, the protein half-life of
pro–caspase-3 was shortened as a result of increased
ubiquitination and degradation. Due to a key role played by
caspase-3 in mediating apoptosis, the level of pro–caspase-
3 in unstressed cells would determine the threshold of cellular
sensitivity to apoptosis induced by agents that activate either
the death receptor pathway or the mitochondrial apoptosis
pathway. Indeed, it has been shown that pro–caspase-3–
deficient mice had decreased apoptosis in the brain with
premature lethality [45]. In cultured cells, reduction or inacti-
vation of pro–caspase-3 dramatically reduced apoptosis in
diverse settings, including resistance to apoptotic-inducing
anticancer agents, whereas overexpression of pro–caspase-
3 increased apoptosis at both basal and induced levels
[8,46–49]. We further showed here that accumulation of
pro–caspase-3 level can be achieved by siRNA silencing of
SAG, ROC1, or b-TrCP, which led to increased caspase-3
activity and apoptosis induction on exposure to etoposide and
TRAIL. Thus, it appears that the level of pro–caspase-3
Figure 6. Silencing of SCF components results in caspase-3 activation and apoptosis induction. (A) Silencing of SAG, ROC1, or -TrCPs increased caspase-3
activity upon activation and (B) cell death induced by anticancer agents. HeLa cells were transfected with psiSAG-2, psiROC-1, or -TrCP-si alone, along with
psiCont plasmid. Thirty-six hours posttransfection, cells were treated with either DMSO or etoposide (25 M) for 24 hours, or TRAIL (50 ng/ml) for 8 hours, followed
by caspase-3 activity assay (A) or trypan blue staining assay for cell viability (B). The results were presented as percent control (mean ± SEM) from three
independent experiments. Paired Student’s t test was used to define statistically significant levels at *P < .05 or **P < .01.
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contributes to cellular apoptosis threshold, and approaches
that increase the cellular level of pro–caspase-3 would
enhance caspase-3 activity on activation, leading to an
increased sensitivity to apoptosis. We propose that anti-
apoptosis activity of SAG could be mediated through the
activation of SCFb-TrCP E3 ligase to promote the ubiquitination
and degradation of pro–caspase-3, thus reducing the basal
level of pro–caspase-3 to increase apoptosis threshold.
It has been shown recently that pro–caspase-3 level was
decreased in some carcinomas of the prostate, colon, and
breast [46,47,50–52], whereas levels of SAG or b-TrCP
were increased in a subset of human colon, pancreatic,
and lung cancers [20,32,43,44,53]. Future research is di-
rected at identifying a subset of human cancer cells with an
increased expression of SAG/b-TrCP and a decreased ex-
pression of pro–caspase-3 to determine whether targeting
SAG/b-TrCP through siRNA or SAG–SCFb-TrCP E3 Ub ligase
with a small molecule inhibitor such as pyrrolidine dithio-
carbamate [54] would increase pro–caspase-3 level, induce
apoptosis, and/or sensitize these cells to chemotherapy or
radiotherapy. This would further validate SAG–SCFb-TrCP
E3 ligase as a promising cancer target for novel anticancer
drug discovery [55].
Earlier studies have demonstrated that substrates of
SCFb-TrCP E3Ub ligase contain a b-TrCP–consensus binding
motif (destruction motif) DSGxxS with both serine residues
phosphorylated before b-TrCP binding [56–58]. Recent
studies revealed some degeneracy in this motif requirement
for b-TrCP binding. It has been shown that b-TrCP bound to
ATF4 [33] and the NFnB1 precursor p105 [59] through a
DSGxxxS motif, to Cdc25A through a DSGxxxxS motif [60],
and to Wee1 that lacks a consensus motif, with two phos-
phate serine residues far apart from each other [61]. Most
recently, b-TrCP has been shown to bind to a previously un-
described nonphosphorylated destruction motif (DDGfXD,
enriched in acidic residues) in Cdc25A and Cdc25B [62]. In
the case of pro–caspase-3, we identified two putative
b-TrCP–binding sites with some degeneracy: one is at
28DSGI.S (one amino acid missing between residues G and
S) and the second is at 175DSGVDD (an S!D substitution at
the second serine residue). Among all caspases examined at
the corresponding regions [63], only pro–caspase-7 has a
degeneracy site: 198DSGPIN. However, pro–caspase-7 did
not bind to b-TrCP (data not shown).We showed here that the
first 38 amino acids are required for b-TrCP binding. The fact
that the deletions of this sequence, which also completely
deleted the first potential b-TrCP–binding site, abolished
such binding suggested that the 28DSGI.S motif might be
important for binding. However, our further analysis using
site-directed mutants indicated that b-TrCP/pro–caspase-3
binding requires neither degenerated DSGxxS motif nor
DDGfXD motif because: 1) S!A mutations at both putative
bindingmotifs did not abolish their binding; 2) S!Dmutations
that constitutively mimic serine phosphorylation did not en-
hance binding; and 3) D!A mutations at 28D and 34D, or at
175D and 179,180,181D (to abolish acidic residues) did not
abolish their binding (unpublished data). Thus, due to this
unconventional nature of b-TrCP/pro–caspase-3 binding, we
cannot exclude the possibility that other cellular protein(s)
may also be involved in the b-TrCP/pro–caspase-3 complex
that would facilitate pro–caspase-3 degradation.
In summary, we identified pro–caspase-3 as a substrate
for SAG/ROC–SCFb-TrCP E3 Ub ligase. It appears that the
ligase-associated mechanism by which SAG protects cells
from apoptosis is mediated, at least in part, by binding and
ubiquitinating/degrading pro–caspase-3, leading to an in-
creased apoptosis threshold and reduced apoptosis.
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